Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageWe are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. We have approved medicines for cystic fibrosis (“CF”), sickle cell disease (“SCD”), transfusion dependent beta thalassemia (“TDT”), and acute pain, and we continue to serially innovate and advance next-generation clinical and research programs in these areas.
In the company’s own words · 10-K filed Feb 13, 2026 · SEC EDGAR
Business segments
Q1 2026 · $2.99BThe company’s own SEC segment disclosure.
- TRIKAFTAKAFTRIO$2.35B79%
- ALYFTREK$424.4M14%
- Manufactured Product Other$135.9M5%
- CASGEVY$42.9M1%
- JOURNAVX$29.0M1%
Vertex Pharmaceuticals (VRTX) reported revenue of $3.33B in Q2 2026 (quarter ended June 30, 2026), up 12% from the same quarter a year earlier. That came with a gross margin of 85% and net income of $1.10B (33% of revenue). For the full year FY2025, revenue was $12.0B (+8.9% year on year) and net income $3.95B. Its largest product in 2026-Q1 was TRIKAFTAKAFTRIO at $2.35B, 79% of the disclosed total, just ahead of ALYFTREK at 14%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.